Xtant Medical Holdings Inc (XTNT)
Official siteHEALTHCARE • MEDICAL DEVICES • AMEX
Market Cap: $38.12M
Last updated: Nov 17, 2026 at 11:05 AM ET
Xtant Medical Holdings Inc (XTNT) Earnings: Report Dates and Results
Xtant Medical Holdings (XTNT) is expected to report earnings on Mar 29, 2027. In the quarter ended Jun 30, 2026, Xtant Medical Holdings reported EPS of -$0.07, below the -$0.02 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
XTNT has an expected report date of Mar 29, 2027.
XTNT Earnings Call
The latest XTNT earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 33 quarters below that had an estimate, XTNT beat 15, missed 12 and matched 6. Revenue for the quarter ended Jun 30, 2026 was $23.03M, down 35.0% from $35.41M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.07 | -$0.02 | -$0.02 - -$0.02 | -250.00% | Miss | -333.3% | 2 | 0 up, 1 down | Aug 11, 2026 | $23.03M |
| Mar 31, 2026 | -$0.02 | -$0.02 | -$0.02 - -$0.02 | 0.00% | In line | -300.0% | 1 | 0 up, 1 down | May 13, 2026 | $20.88M |
| Dec 31, 2025 | -$0.01 | -$0.01 | N/A | -182.00% | Miss | N/A | 1 | 0 up, 1 down | Mar 31, 2026 | $32.36M |
| Sep 30, 2025 | $0.01 | -$0.01 | N/A | +200.00% | Beat | N/A | 1 | 1 up, 0 down | Nov 10, 2025 | $33.26M |
| Jun 30, 2025 | $0.03 | -$0.02 | -$0.02 - -$0.02 | +250.00% | Beat | N/A | 1 | 0 up, 0 down | Aug 12, 2025 | $35.41M |
| Mar 31, 2025 | $0.01 | -$0.01 | -$0.01 - -$0.01 | +200.00% | Beat | N/A | 1 | 1 up, 0 down | May 12, 2025 | $32.90M |
| Dec 31, 2024 | -$0.01 | -$0.02 | -$0.02 - -$0.02 | +33.00% | Beat | N/A | 1 | 0 up, 1 down | Mar 6, 2025 | $31.51M |
| Sep 30, 2024 | -$0.04 | -$0.02 | -$0.03 - -$0.02 | -100.00% | Miss | -157.1% | 2 | 0 up, 0 down | Nov 12, 2024 | $27.94M |
| Jun 30, 2024 | -$0.02 | -$0.02 | -$0.02 - -$0.02 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Aug 8, 2024 | $29.94M |
| Mar 31, 2024 | -$0.02 | -$0.02 | -$0.02 - -$0.01 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Apr 1, 2024 | $27.87M |
| Dec 31, 2023 | -$0.03 | -$0.02 | -$0.03 - -$0.02 | -50.00% | Miss | N/A | 2 | 0 up, 0 down | Feb 13, 2024 | $28.11M |
| Sep 30, 2023 | $0.07 | -$0.01 | N/A | +800.00% | Beat | N/A | N/A | 0 up, 0 down | Nov 9, 2023 | $25.02M |
| Jun 30, 2023 | -$0.02 | -$0.02 | -$0.02 - -$0.02 | 0.00% | In line | N/A | 1 | 0 up, 0 down | Aug 1, 2023 | $20.23M |
| Mar 31, 2023 | -$0.02 | -$0.03 | -$0.03 - -$0.03 | +33.33% | Beat | N/A | 1 | 0 up, 0 down | May 4, 2023 | $17.94M |
| Dec 31, 2022 | -$0.02 | -$0.02 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 7, 2023 | $15.27M |
| Sep 30, 2022 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 3, 2022 | $14.46M |
| Jun 30, 2022 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 4, 2022 | $15.28M |
| Mar 31, 2022 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 5, 2022 | $12.96M |
| Dec 31, 2021 | -$0.03 | -$0.03 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 8, 2022 | $13.97M |
| Sep 30, 2021 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 12, 2021 | $13.78M |
| Jun 30, 2021 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 5, 2021 | $14.97M |
| Mar 31, 2021 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | May 11, 2021 | $12.54M |
| Dec 31, 2020 | -$0.01 | -$0.12 | N/A | +91.67% | Beat | N/A | N/A | 0 up, 0 down | Feb 24, 2021 | $14.01M |
| Sep 30, 2020 | -$0.10 | -$0.11 | -$0.11 - -$0.11 | +9.09% | Beat | N/A | 1 | N/A | Oct 29, 2020 | $14.02M |
| Jun 30, 2020 | -$0.19 | -$0.11 | -$0.11 - -$0.11 | -72.73% | Miss | N/A | 1 | N/A | Aug 3, 2020 | $10.53M |
| Mar 31, 2020 | -$0.19 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 7, 2020 | $14.78M |
| Dec 31, 2019 | -$0.12 | -$0.21 | -$0.21 - -$0.21 | +42.86% | Beat | N/A | 1 | N/A | Mar 5, 2020 | $16.96M |
| Sep 30, 2019 | -$0.14 | -$0.28 | -$0.28 - -$0.28 | +50.00% | Beat | N/A | 1 | N/A | Nov 7, 2019 | $15.72M |
| Jun 30, 2019 | -$0.15 | -$0.52 | N/A | +71.15% | Beat | N/A | N/A | N/A | Aug 8, 2019 | $15.27M |
| Mar 31, 2019 | -$0.21 | -$0.36 | -$0.54 - -$0.18 | +41.67% | Beat | N/A | 2 | N/A | Apr 1, 2019 | $16.73M |
| Dec 31, 2018 | -$0.23 | -$0.32 | -$0.32 - -$0.32 | +28.13% | Beat | N/A | 1 | N/A | Dec 31, 2018 | $18.26M |
| Sep 30, 2018 | -$0.24 | -$0.19 | N/A | -26.32% | Miss | N/A | N/A | N/A | Nov 14, 2018 | $17.27M |
| Jun 30, 2018 | -$0.38 | -$0.27 | -$0.27 - -$0.25 | -40.74% | Miss | N/A | 2 | N/A | Aug 7, 2018 | $18.74M |
| Mar 31, 2018 | -$0.54 | -$0.38 | N/A | -42.11% | Miss | N/A | N/A | N/A | Apr 2, 2018 | $17.93M |
| Dec 31, 2017 | -$18.77 | -$3.49 | -$4.70 - -$2.28 | -437.82% | Miss | N/A | 2 | N/A | Mar 30, 2018 | $19.33M |
| Sep 30, 2017 | -$5.64 | -$5.76 | N/A | +2.12% | Beat | N/A | N/A | N/A | Nov 21, 2017 | $19.79M |
| Jun 30, 2017 | -$6.18 | -$1.20 | N/A | -415.00% | Miss | N/A | N/A | N/A | Aug 9, 2017 | $21.41M |
| Mar 31, 2017 | -$3.48 | -$3.54 | N/A | +1.69% | Beat | N/A | N/A | N/A | May 9, 2017 | $22.08M |
| Dec 31, 2016 | -$3.30 | -$2.64 | N/A | -25.00% | Miss | N/A | N/A | N/A | Mar 9, 2017 | $24.47M |
| Sep 30, 2016 | -$4.31 | -$3.84 | N/A | -12.24% | Miss | N/A | N/A | N/A | Nov 7, 2016 | $23.09M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.04, a profit after a loss of $0.09 per share the year before. It was -$16.93 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.04 | N/A |
| Dec 31, 2024 | -$0.09 | N/A |
| Dec 31, 2023 | $0.00 | N/A |
| Dec 31, 2022 | -$0.10 | N/A |
| Dec 31, 2021 | -$0.07 | N/A |
| Dec 31, 2020 | -$0.49 | N/A |
| Dec 31, 2019 | -$0.62 | N/A |
| Dec 31, 2018 | -$1.39 | N/A |
| Dec 31, 2017 | -$34.07 | N/A |
| Dec 31, 2016 | -$16.93 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 3,100 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 3,071 | 7 | |
| 2025Q4 | Dec 31, 2025 | 4,114 | 6 | |
| 2025Q3 | Sep 30, 2025 | 3,990 | 6 | |
| 2025Q2 | Jun 30, 2025 | 3,094 | 6 | |
| 2025Q1 | Mar 31, 2025 | 3,476 | 6 | |
| 2024Q4 | Dec 31, 2024 | 3,571 | 5 | |
| 2024Q3 | Sep 30, 2024 | 3,689 | 5 |
2026Q1 Earnings Call
Opening remarks
Kevin Gardner Host / Investor Relations Thank you, operator, and welcome to Xtant Medical's First Quarter 2026 Financial Results Call. Joining me today are Sean Browne, President and Chief Executive Officer; and Scott Neils, Chief Financial Officer. Today's call is being webcast and will be posted on the company's website for playback. During the course of this call, management may make certain forward-looking statements regarding future events and the company's expected future performance. These forward-looking statements reflect Xtant's current perspective on existing trends and information and can be identified by such words as expect, plan, will, may, anticipate, believe, should, intends and other words with similar meaning. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in the Risk Factors section of the company's annual report on the Form 10-K filed with the SEC and in subsequent SEC reports and press releases. Actual results may differ materially. The company's financial results press release and today's discussion include certain non-GAAP financial measures. Please refer to the non-GAAP to GAAP reconciliations, which appear in our press release and are otherwise available on our website. Note that the Form 8-Ks that we filed with our financial results press releases provide detailed narratives that describe our use of such measures. For the benefit of those of you who may be listening to a replay, this call was held and recorded on May 13, 2026, at approximately 8:30 a.m. Eastern Time. The company declines any obligation to update its forward-looking statements, except as required by applicable law. Now I'd like to turn the call over to Sean Browne, CEO. Sean?
Sean Browne President and Chief Executive Officer Thank you, Kevin, and good morning, everyone. Thank you for joining our first quarter update call. As has been our practice, I'll begin with a few prepared remarks about our operations, and then Scott will provide a deeper dive into the financials. We will then open the call to your questions. Since our last quarterly update, Xtant Medical has achieved multiple significant milestones that position us for sustained growth. We strengthened our balance sheet with proceeds from the Companion Spine transaction, secured a transformational license agreement with Dilon Technologies that moves us into the multibillion-dollar hemostatic agent market and advanced our innovation track record with the commercial launch of Trivium Shaped. With that as a backdrop, we are raising our full year 2026 revenue guidance to $101 million to $105 million. First, I'd like to begin this morning with a recap of the Dilon Technologies distribution agreement that we announced in April. Through this agreement, we acquired exclusive U.S. distribution rights to Dilon's HEMOBLAST Bellows product for high-performance hemostasis following certain surgical procedures.
Frequently Asked Questions About XTNT
When is Xtant Medical Holdings's next earnings date?
Xtant Medical Holdings's next earnings report is expected for Mar 29, 2027.
Did XTNT beat earnings estimates last quarter?
No. Xtant Medical Holdings reported EPS of -$0.07 for the quarter ended Jun 30, 2026, below the -$0.02 estimate by 250.00%.
What EPS do analysts expect from XTNT next quarter?
The consensus EPS estimate for Xtant Medical Holdings for the quarter ending Dec 31, 2026 is $0.00 from 5 analysts, with estimates from -$0.01 to $0.00.
How often does XTNT beat earnings estimates?
Xtant Medical Holdings beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +18.88%.
XTNT pages: Overview, Earnings, Forecast, Financials, Competitors